Ignite Creation Date:
2024-05-06 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 1:52 PM
Study NCT ID:
NCT04686994
Status:
COMPLETED
Last Update Posted:
2021-04-08
First Post:
2020-12-23
Brief Title:
Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects
Sponsor:
Gannex Pharma Co Ltd
Organization:
Gannex Pharma Co Ltd
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Phase Ib Study to Evaluate Safety Tolerability and Pharmacokinetics and Pharmacodynamics Biomarkers of ASC41 Tables in Overweight and Obese Subjects
Status:
COMPLETED
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study is to evaluate the safety tolerability and compare the pharmacokinetic parameters of ASC41 a THR beta agonist tables in overweight and obese subjects who have elevated LDL-C
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None